



Docket No. 1747

**CERTIFICATE OF MAILING (37 CFR 1.8 (a))**

I hereby certify that the attached papers or fee are being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

Date: December 31, 2002

Printed Name: Marie M. Greloch

Signature: Marie Greloch

RECEIVED  
JAN 09 2003  
TECH CENTER 1500/2800

**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

**Application of:** Hakan Nyqvist et al.

**Serial Number:** 09/077,718

**Group Art Unit:** 1626

**Filed:** June 8, 1998

**Examiner:** T. Solola

**For:** A New Salt

**AMENDMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Please amend the application as follows:

In the claims:

--23 (New). The salt (R) – N, N-dicyclobutylamino-8fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R, 3R)-tartrate, wherein said salt is physically stable, has good solubility, and has good dissolution properties.

24 (New). A pharmaceutical formulation containing, as an active ingredient, the salt as recited in claim 1.

25 (New). A method for the treatment of 5-hydroxytryptamine<sub>1A</sub>-receptor-antagonist-activity-related central nervous system disorders or so related thermoregulatory disturbances, sexual disturbances, disturbances in the cardiovascular system or disturbances in the gastrointestinal system comprising administering, to a host in need of such treatment, an effective amount of the salt according to claim 23.